COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01633580
Recruitment Status : Completed
First Posted : July 4, 2012
Last Update Posted : December 3, 2014
Information provided by (Responsible Party):
Blockeel Christophe, Universitair Ziekenhuis Brussel

Brief Summary:
The purpose of the present study is to analyse if corifollitropin alfa, an agent for prolonged ovarian stimulation, administered from day 4 can be clinically used instead of day 2 onwards for a controlled ovarian hyperstimulation (COH) in an antagonist protocol.

Condition or disease Intervention/treatment Phase
Infertility Drug: corifollitropin alfa Phase 4

Detailed Description:
Corifollitropin alfa is a new recombinant gonadotrophin with sustained follicle-stimulating activity. It offers novel and effective treatment option for potential normal responder patients undergoing ovarian stimulation with GnRH antagonist co-treatment for IVF or in vitro fertilisation resulting in a high ongoing pregnancy rate, equal to that achieved with daily rFSH. Normally, this medication is started on day 2 of the cycle. In the present randomised trial, we want to evaluate whether this agent can be clinically used when started on day 4 of the cycle.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Follicular Phase Endocrine Characteristics During Ovarian Stimulation and GnRH Antagonist Co-treatment for IVF; Randomized Trial Comparing Corifollitropin Alfa (Elonva) Initiated on Cycle Day 2 or 4.
Study Start Date : December 2011
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Arm Intervention/treatment
Placebo Comparator: Day 2 group
Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.
Drug: corifollitropin alfa
long acting FSH

Active Comparator: Day 4 group
Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa
Drug: corifollitropin alfa
long acting FSH

Primary Outcome Measures :
  1. Consumption of rFSH at the end of the follicular phase [ Time Frame: up to 9 months ]
    The purpose is to assess the additional need for recFSH in each treatment group

Secondary Outcome Measures :
  1. Pregnancy rate [ Time Frame: Up to 9 months ]
    The purpose is to study the pregnancy rate in each treatment group

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 36 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • < 36 years old on day of randomisation
  • FSH < 12 (in the early follicular phase)
  • Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.
  • Regular menstrual cycles of 21-35 days, presumed to be ovulatory.
  • BMI ≤ 29
  • Weight > 60 kg
  • < 3 previous trials
  • ICSI
  • Randomisation at out-patient clinic

Exclusion Criteria:

  • ≥ 36 years old on day of randomisation
  • Endometriosis ≥ grade 3
  • PCOS
  • Poor responders (development of < 4 follicles in a previous IVF/ICSI cycle)
  • Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01633580

Layout table for location information
UZ Brussel
Jette, Belgium, 1090
Sponsors and Collaborators
Universitair Ziekenhuis Brussel
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Blockeel Christophe, MD, PhD, Universitair Ziekenhuis Brussel Identifier: NCT01633580    
Other Study ID Numbers: 2012/019
First Posted: July 4, 2012    Key Record Dates
Last Update Posted: December 3, 2014
Last Verified: December 2014
Keywords provided by Blockeel Christophe, Universitair Ziekenhuis Brussel:
GnRH antagonist
corifollitropin alfa
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female